Scientific Investment in Precision Oncology with Sadie Dobrozsi, MD

In this episode, host Shikha Jain, MD, speaks with Sadie Dobrozsi, MD, about the power of information in personalized oncology care, understanding the impacts of genetic testing and more. • Welcome to another exciting episode of Oncology Overdrive 1:34 • About Dobrozsi 1:39 • The interview 2:03 • What was your path to this field of pediatric oncology, and how did you decide to focus on genetic testing? 2:33 • Can you talk about what it means to use genomics to optimize therapy and tailor precision medicine, and how you implement that in your work? 7:58 • Why is it so important to continue focusing on funding precision medicine as an advancement in cancer care? 10:34 • Can you talk about your work with BRCA research and how treatment and surgeries have evolved with our understanding of it? 14:30 • Jain and Dobrozsi on the importance of shared decision-making in oncology, and how genomics plays a role in that ongoing conversation. 20:18 • How do we navigate difficult conversations with increasingly younger patient populations, and why are we having these conversations more now than ever before? 23:55 • When it comes to genetic testing, how much knowledge is "good knowledge"? 27:05 • If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 34:31 • How to contact Dobrozsi 35:12 • Thanks for listening 35:39 Sadie Dobrozsi, MD, is a board-certified pediatric oncologist, a nationally recognized leader in complex care delivery, and the medical director of genetic testing and oncology imaging at Evolent, a leading specialty and primary care management company.

We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Dobrozsi can be reached on LinkedIn or via email sdobrozsi@evolent.com.

Disclosures: Jain and Dobrozsi report no relevant financial disclosures.